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doubled when we changed rinses for gel
rubs in care units. We did not change to
gels for surgical hand disinfection but
kept a hand rinse.
Third, Kramer and colleagues put the
gel effect before the composition effect.
However, the type and number of
associated alcohols are perhaps more
important than the carrier formulation.
In future gels, which are becoming
increasingly fluid and easy to apply, may
become as efficient as rinses and as well
tolerated as old gels.
Another important issue is efficacy of
hand rubs on viruses, which is awaiting
European testing. Although, however,
the efficacy of the product should be a
criterion, if our target is the reduction of
nosocomial infections, tolerance and
acceptability by health-care workers are
also important.
*Raphaële Girard, Ludwig Serge Aho, 
Marie Louise Goetz, Jean Claude Labadie,
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We fully agree with John Boyce and
colleagues, Peter Hoffman and
colleagues, and Dan Diekema that more
clinical data are necessary to assess the
effectiveness of hand gels. To clarify the
issues under discussion, the ultimate
goal of hand hygiene is to reduce cross-
transmission and infection rates and two
main features contribute—adherence to
recommendations and agent efficacy. 
We have shown previously that
factors that determine adherence are
multiple,1,2 but one is health-care
workers’ acceptance of agents. The
concern that rinses might be less
accepted than gels is legitimate.
Nevertheless, no data yet suggest that
adherence is higher when using gels than
when using rinses, although the impact
on attitudes of an excessively market-
driven, health-care industry is clear.3
Moreover, in one study, fewer than half
of health-care workers were satisfied
with a newly introduced gel, and more
than half found it uncomfortable to use,
which threatened adherence (table).4 To
our knowledge, the only reported
experience of successful and sustained
hand hygiene promotion with a parallel
drop in nosocomial infection used a
rinse.2 
We recognise that despite the
availability of standard laboratory tests
and, especially EN 1500, in no clinical
trial has the extent to which hand
microbial counts need to be reduced to
decrease cross-transmission been
established. Whether the difference in
log reduction between rinses and gels is
clinically important remains unknown.
However, if we assume an identical
degree of acceptance, the agent with
greater efficacy should be favoured until
more data from controlled clinical trials
are available. 
We believe our data raise concern that
should stimulate researchers and
manufacturers to invest in the
development of agents with maximum
antimicrobial efficacy, tolerance, and
acceptance. Increase of the ethanol
content of gels is one step towards
improved efficacy. To end the
controversy, we invite the scientific
community to collaborate to decide
international norms for the testing of
hand rubs, especially in hospitals, and
ideally to assess the dynamics of hand
contamination.5
In health-care institutions where hand
washing with medicated soap is still
used, we strongly recommend a change
to use of alcohol-based hand rubs,
whether rinses or gels, whichever
produces the best adherence. In
hospitals where adherence has improved
and infection rates decreased because of
rinse use,2 we are tempted to say don’t
change a winning team. 
Adherence to hand hygiene is a
complex behavioural issue; successful
promotion strategies should use
multiple methods.1,2,4 Efficacy, accepta-
bility, and good skin tolerance of hand
rubs are important but are only one
brick in the wall of adherence.
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Authors’ reply
Sir—Alcohol-based hand rubs approved
for use, whether gels or rinses, reduce
bacterial counts on health-care workers’
hands more than do antimicrobial soaps
or detergents.1 Rubs are fast-acting, and




Overall, I was satisfied with the hand gel 45% 34% 21%
The gel helped to improve my hand hygiene adherence 42% 23% 35%
The gel was conveniently located 57% 29% 14%
The gel caused less skin irritation than did handwashing 42% 29% 29%
The gel caused a sticky, uncomfortable feeling 53% 24% 23%
Adapted with permission from reference 4.




Sir—H De Boer and colleagues (May
11, p 1666)1 describe an adolescent
who died 4 days after a car accident.
Postmortem diagnosis revealed meta-
static testicular cancer. In their
accompanying May 11 Commentary,
Jeremy Steel and R Timothy Oliver2
discuss the perils of very late
presentation of testicular cancer.
De Boer and colleagues and Steel
and Oliver offer several explanations
for late presentation. We have started 
a study on reasons for delay in
testicular cancer. On the basis of
reports on delay and disease-specific
characteristics of testicular cancer, we
developed a questionnaire to assess
possible characteristics of patients’ and
doctors’ delay. 
25 testicular-cancer patients,
median age 23 (range 16–43) years,
have so far completed the
For personal use. Only reproduce with permission from The Lancet Publishing Group.
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questionnaire. Median time between
awareness of an unexplained symptom
and seeking medical consultation was
35 (1–365) days. 12 patients knew of
testicular cancer as a disease before
diagnosis, but knowledge was not
significantly correlated with delay. 21
patients mentioned a change in the
testicle as a first symptom, three
reported other symptoms (back pain,
gynaecomasty) before they discovered
a change in the testicle, and one never
noted a change in his testicle.
Of the 24 patients who reported an
abnormal testicle, only four thought of
cancer as a possibility, ten had no
explanation, and ten attributed their
symptoms to another illness. Six
patients expressed embarrassment
about the abnormality in the testicle.
Embarrassment was strongly related 
to patients’ delay. All 24 patients
consulted their family physicians 
about the abnormality in the testicle
and ten were immediately referred 
for further examination. The
remaining 14 patients were initially
misdiagnosed, which led to delays of
up to 112 days, although the median
doctor delay was only 12 days. 
The median delay for patients and
doctors is limited, but the range is
large. An unanticipated result was that
interpretation of symptoms was an
important determinant of delay,
whereas patients’ knowledge of
testicular cancer seemed unimportant.
The low prevalence of testicular cancer
and vagueness of the symptoms
augment the chances for misinter-
pretation. Delay in diagnosis of the
disease may lead to more extensive
disease, combined methods of treat-
ment, and a reduction in disease-free
survival.3 Therefore, family physicians
should always bear testicular cancer in
mind when adolescents and young
men present with inguinal or scrotal
complaints.
We agree with Steele and Oliver,
that continuous education is needed
for patients as well as medical
professionals to alert them to the fact
that testicular abnormalities may
constitute medical emergencies.
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Use of galantamine to
treat vascular dementia
Sir—The masking of treatment
assignment prevents bias at several
stages of randomised controlled trials.
Doubts on this pivotal trial feature are
legitimate for Timo Erkinjuntti and
colleagues’ study (April 13, p 1283)1 of
galantamine in dementia.
In obtaining consent for randomi-
sation, patients and caregivers are
informed of potential adverse effects of
the drug under study. As with all
cholinesterase inhibitors, galantamine
has notable cholinomimetic side-effects.
The frequency of nausea (24%) and
vomiting (13%) reported in the
galantamine group was substantially
higher than that in the placebo group
(7% and 6%, respectively). Given the
high frequency of gastrointestinal side-
effects and the knowledge of its hidden
meaning in physicians, patients, and
caregivers, it is highly unlikely that the
masking of treatment was maintained
throughout the entire study period for
all patients. 
Erkinjuntti and colleagues do not
address the issue of unintentional loss of
blinding similar to other studies on
cholinesterase inhibitors, blinding at the
time of randomisation is simply stated
as a matter of fact, but data are lacking
that support its success rate and
preservation throughout the study. The
burden of proof for effective blinding,
however, rests on the investigators. At
the last visit, patients, caregivers, and
physicians should be asked to guess
what treatment was provided. If the
number of correct responses does not
exceed the level of chance, it is
reasonable to assume that blinding was
successfully maintained. If such
hindsight on blinding is not provided,
however, there is room to speculate that
small effect sizes, such as noted by
Erkinjuntti and colleagues, may be due
to bias that is based on knowledge of
treatment assignment in patients,
caregivers, or physicians. 
W A van Gool
Department of Neurology, Academic Medical
Centre, University of Amsterdam, PO Box
22700, 1100 DE Amsterdam, Netherlands
(e-mail: w.a.vangool@amc.uva.nl)
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Sir—Timo Erkinjuntti and colleagues’
report on galantamine1 will fuel the
debate over whether cholinesterase
inhibitors are a rational treatment
choice for patients with vascular
dementia. Despite evidence from
preclinical and postmortem studies
that the pathological changes in
vascular dementia seem to be
associated with cholinergic deficits,
some experts remain unconvinced.
Erkinjuntti and colleagues provide
convincing evidence that the
acetylcholinesterase-selective inhibitor
galantamine is effective in patients who
have Alzheimer’s disease with
cerebrovascular disease (mixed
dementia). However, galantamine
provided no significant benefit over
placebo in patients with pure vascular
dementia. The researchers suggest that
this lack of effect was due to the study
not being powered to detect
significance in the pure vascular
dementia subgroup, and because there
was a slow placebo decline.1 However,
the results will inevitably be interpreted
by some critics to suggest that the
efficacy of galantamine in mixed
dementia stemmed only from the
drug’s effects on the Alzheimer’s
features of the disorder.
We challenge such interpretations
and express our support for the
continued study of cholinesterase
inhibitors in patients with vascular
dementia. Existing data provide
evidence that the cholinergic hypo-
thesis is applicable, and that
cholinesterase inhibitors may provide
benefits in patients who have dementia
with a vascular component.
We have published data from a small
study in patients with frontosubcortical
vascular dementia, showing that
3–6 mg rivastigmine daily—an acetyl-
cholinesterase inhibitor and butyryl-
cholinesterase—improved executive
function and behaviour for 12 months,
compared with baseline and a control
group receiving cardioaspirin.2 These
are the two domains that characterise
frontosubcortical vascular dementia.
These benefits were maintained over 
22 months of treatment3 and may
reflect the drug’s effects on the
cholinergic system, and its particular
activity in frontal areas of the brain.4
Furthermore, Kumar and colleagues,5
in a large randomised study, showed
that rivastigmine provided even greater
benefits in patients with Alzheimer’s
disease and vascular disease than in
patients with pure Alzheimer’s disease.
Rivastigmine was well tolerated in both
studies.2,3,5
We agree with Erkinjuntti and
colleagues that there may be a
cholinergic deficit in patients with
